Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating patient immune reponse as a biomarker and theraputic target advanced prostate cancer

FY 2018-19

Summary
High grade prostate cancer (PCa) patients are at risk of developing metastases despite radiotherapy. A study found that patients treated with brachytherapy (BT) and EBRT (external beam radiotherapy) had a lower rate of metastases compared to EBRT alone1. It is hypothesized that the high radiation of BT results in significant tumour death, priming the immune system to recognize tumour cells. High risk patients (BT+EBRT (n=25) and EBRT (n=25)) will have blood drawn before, during, and after treatment. Changes in peripheral immune cell composition will be assessed and correlated with patient response. This will provide evidence that BT induces a distinct immunological response compared to EBRT alone. High grade PCa patients are also at risk of recurrence following radiotherapy. A study discovered that tumours made resistant to cisplatin were more responsive to PDL1 checkpoint inhibitor than parental tumours2. The enhanced PDL1 blockade sensitivity was a result of greater mutational load, generating neoantigens which triggered an immune response. A mouse PCa cell line will be treated with radiation to generate radiorecurrent cells. Mice will be transplanted with parental or radiorecurrent cells, administered PDL1 inhibitor or control, and mock irradiated or irradiated. Blood will be drawn from mice before, during, and after radiation and lymphocyte composition will be measured. Whole exome sequencing will allow comparison of mutational load between in radiorecurrent cells and parentals. The proposed research can potentially identify new therapeutic biomarkers and allow usage of immune checkpoint therapy as a novel approach to salvage radiorecurrent tumours. 1Kishan et al., Eur Urol 2017 71(5):766-773 2Kuczynski et al., Mol Cancer Ther 2018 17(4):869-882
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
411306
Name
Wang Hanzhi
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating patient immune reponse as a biomarker and theraputic target advanced prostate cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Brachytherapy; External Beam Radiation; Immune Response; Patient Samples; Pd-L1; Prostate Cancer; Radiation; Syngeneic Mouse Model
Abstract
High grade prostate cancer (PCa) patients are at risk of developing metastases despite radiotherapy. A study found that patients treated with brachytherapy (BT) and EBRT (external beam radiotherapy) had a lower rate of metastases compared to EBRT alone1. It is hypothesized that the high radiation of BT results in significant tumour death, priming the immune system to recognize tumour cells. High risk patients (BT+EBRT (n=25) and EBRT (n=25)) will have blood drawn before, during, and after treatment. Changes in peripheral immune cell composition will be assessed and correlated with patient response. This will provide evidence that BT induces a distinct immunological response compared to EBRT alone. High grade PCa patients are also at risk of recurrence following radiotherapy. A study discovered that tumours made resistant to cisplatin were more responsive to PDL1 checkpoint inhibitor than parental tumours2. The enhanced PDL1 blockade sensitivity was a result of greater mutational load, generating neoantigens which triggered an immune response. A mouse PCa cell line will be treated with radiation to generate radiorecurrent cells. Mice will be transplanted with parental or radiorecurrent cells, administered PDL1 inhibitor or control, and mock irradiated or irradiated. Blood will be drawn from mice before, during, and after radiation and lymphocyte composition will be measured. Whole exome sequencing will allow comparison of mutational load between in radiorecurrent cells and parentals. The proposed research can potentially identify new therapeutic biomarkers and allow usage of immune checkpoint therapy as a novel approach to salvage radiorecurrent tumours. 1Kishan et al., Eur Urol 2017 71(5):766-773 2Kuczynski et al., Mol Cancer Ther 2018 17(4):869-882
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Wang, Hanzhi
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~